News

The approval was given on the basis of results from prospective, open-label, single-arm Phase II study, in which 75% of patients (21 of 28) experienced a reduction of

The company has posted a net loss of $2.69m for the third quarter 2011, or $0.13 loss per diluted share, compared to net loss of $2.71m, or $0.15

The company has reported a net loss of $22.93m, or $0.69 loss per diluted share, compared to net loss of $18.58m or $0.58 loss per diluted share, for

Administered as a muco-adhesive buccal tablet, Loramyc is an antifungal agent indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients. As per the terms of the agreement,

In addition to the drug-drug, drug-allergy, drug-food and drug-herbal checks, PEPID’s drug interaction checker also provides alerts for duplicate therapy on three different levels -therapeutic class, pharmacologic class

The company has reported a net income of $3.19m, or $0.13 loss per diluted share, compared to net income of $1.86m or $0.08 per diluted share, for the

Developed by Allos, Folotyn is a folate analogue metabolic inhibitor, approved in the US to treat of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The tie

Under the pact, Pfenex will engineer production strains and develop early production processes for MedImmune‘s proprietary molecules. The tie up also allows MedImmune to carry forward the preclinical

The study has evaluated 494 adult patients with UC who had not responded well to conventional therapy, such as corticosteroids and/or immunosuppressants. In the trial, 16.5% of the